RT Journal Article
SR Electronic
T1 Contribution of age-related effects to COVID-19 differences of crude fatality ratios in two Argentine provinces between March and August 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.28.20240127
DO 10.1101/2020.11.28.20240127
A1 Bramajo, Octavio Nicolas
A1 Bathory, María Florencia
YR 2020
UL http://medrxiv.org/content/early/2020/11/30/2020.11.28.20240127.abstract
AB The following paper presents temporary estimations of CFR (the ratio between deaths and infected positive cases) attributed to COVID-19 for two provinces in Argentina (Jujuy and Buenos Aires Province), using public data provided by the Argentine Ministry of Health. In order to make comparisons between jurisdictions, we applied a series of exploratory measures (which resulted in excluding many other jurisdictions from the comparison), and later on the Kitagawa decomposition procedure, trying to separate rate (“net” fatality) and structure components (age-attributable effects) from CFR estimations in those provinces. After the decomposition we can observe that between almost non existant differences on average, the magnitude of structure and net rate effects tend to go into different directions across age groups, indicating some premature mortality in Buenos Aires and an excess net CFR in Jujuy for older age-groupsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Given that we used publicly available anonymous data, no ethical concerns were foundAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available freely upon request to the authors